Payment overview · 2025
General Payments
$53,407.58
237 reported records · 20 companies
Healthcare provider profile · identity verified
Saibal Kar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · THOUSAND OAKS, CA · NPI 1063449403
Verified facts
What the public records show
CMS Open Payments records show Saibal Kar, M.D. received $53,407.58 in general payments during 2025 across 237 reported records.
Abbott Laboratories accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26,740.98 | 50.1% | 69 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14,560.61 | 27.3% | 74 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $5,788.39 | 10.8% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $3,173.13 | 5.9% | 47 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $975.09 | 1.8% | 7 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $622.96 | 1.2% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $343.99 | 0.6% | 5 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $208.71 | 0.4% | 3 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $192.54 | 0.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.00 | 0.3% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $150.95 | 0.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $132.01 | 0.2% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $126.29 | 0.2% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $59.49 | 0.1% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $45.25 | 0.1% | 2 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $37.78 | 0.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $29.31 | 0.1% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $22.80 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.19 | 0.0% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $17.11 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $19,860.00 | 6 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,400.00 | 3 |
| Food and Beverage | $9,105.00 | 205 |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,312.50 | 2 |
| Travel and Lodging | $5,669.08 | 20 |
| Education | $61.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $19,216.42 | 23 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $13,905.14 | 43 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $5,788.39 | 10 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM ASD Occluder Normalized: gore cardioform asd occluder |
Device | W. L. Gore & Associates, Inc. | $5,360.00 | 2 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $4,874.04 | 20 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $2,350.78 | 13 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $2,329.23 | 12 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $670.04 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $622.96 | 4 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $550.29 | 28 | 2025 |
Source payment records
|
|||||
| PORTICO Normalized: portico |
Device | Abbott Laboratories | $220.42 | 11 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $192.54 | 1 | 2025 |
Source payment records
|
|||||
| AtriCure cryoICE Cryoablation System (CRYO2) Normalized: atricure cryoice cryoablation system cryo2 |
Device | AtriCure, Inc. | $192.54 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $192.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $161.00 | 3 | 2025 |
Source payment records
|
|||||
| Sentinel Normalized: sentinel |
Device | Boston Scientific Corporation | $158.89 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $150.95 | 1 | 2025 |
Source payment records
|
|||||
| Emerge Push Normalized: emerge push |
Device | Boston Scientific Corporation | $132.02 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $132.01 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $126.29 | 2 | 2025 |
Source payment records
|
|||||
| APOLLOTM Normalized: apollotm |
Device | Medtronic, Inc. | $96.33 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $84.40 | 6 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $81.42 | 1 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $70.87 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $63.41 | 3 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $61.45 | 4 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $61.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $57.94 | 4 | 2025 |
Source payment records
|
|||||
| Vitalyst Normalized: vitalyst |
Device | Boston Scientific Corporation | $57.88 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $56.47 | 2 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $29.31 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $26.34 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| TYKE, PATCH, PLEDGET AND INTRACARDIAC Normalized: tyke patch pledget and intracardiac |
Device | LeMaitre Vascular, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| LINGO Normalized: lingo |
Device | Abbott Laboratories | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTCA Normalized: selution slr ptca |
Device | CORDIS US CORP. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Mailman Normalized: mailman |
Device | Boston Scientific Corporation | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| PAMIRA Normalized: pamira |
Device | BIOTRONIK INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Rivacor 7 DR-T Normalized: rivacor 7 dr t |
Device | BIOTRONIK INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $10.75 | 2 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $10.70 | 2 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $5.92 | 1 | 2025 |
Source payment records
|
|||||
| CONFIDA Normalized: confida |
Device | Medtronic, Inc. | $4.74 | 1 | 2025 |
Source payment records
|
|||||
| ACCUVAC Normalized: accuvac |
Device | Medtronic, Inc. | $4.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Farxiga | Dapagliflozin Propanediol | 31 | 13 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Furosemide | Furosemide | 21 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 19 | 11 |
| Carvedilol | Carvedilol | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53,407.58 · 237 records | Abbott Laboratories | ACCUVAC, AFFERA MAPPING SYSTEM, AMVIA EDGE, AMVUTTRA, APOLLOTM, ATRICLIP LAA EXCLUSION SYSTEM, AVVIGO Guidance System, Acticor 7 VR-T DX, AtriCure cryoICE Cryoablation System (CRYO2), BIOMONITOR, BodyGuardian, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CLOTTRIEVER BOLD CATHETER, CONFIDA, COREVALVE EVOLUT R, EVOQUE, Emerge Push, FARAPULSE, FFRct, GALLANT, GORE CARDIOFORM ASD Occluder, GORE CARDIOFORM Septal Occluder, General - Atherectomy, General - Stents, General - Therapies, LINGO, LifeVest, MITRACLIP, Mailman, NAVITOR, PAMIRA, PASCAL, PORTICO, REPATHA, ROTAPRO, Rhythmia Mapping System, Rivacor 7 DR-T, SELUTION SLR PTCA, SYNERGY ABLATION SYSTEM, Sentinel, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRICLIP, TYKE, PATCH, PLEDGET AND INTRACARDIAC, VYNDAQEL, VersaCross Access Solution, Vitalyst, WATCHMAN, WATCHMAN Access System, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error